GenomeWeb – Stakeholders Urge Collaboration to Prove ctDNA as Regulatory Endpoint for Early Cancer Drugs
NEW YORK – The precision oncology community is hoping it could soon see a new landscape of drug trials using circulating tumor DNA as an early or surrogate endpoint for adjuvant therapies and other treatments in early-stage disease. In a recent draft guidance, the US Food and Drug Administration said that while the evidence isn’t there yet…